Browse SLC5A1

Summary
SymbolSLC5A1
Namesolute carrier family 5 (sodium/glucose cotransporter), member 1
Aliases D22S675; NAGT; sodium/glucose cotransporter 1; SGLT1; Na+/glucose cotransporter 1; high affinity sodium-gluc ......
Chromosomal Location22q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Multi-pass membrane protein.
Domain PF00474 Sodium
Function

Actively transports glucose into cells by Na(+) cotransport with a Na(+) to glucose coupling ratio of 2:1. Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capacity and a high affinity low capacity Na(+)/glucose cotransporter arranged in series along kidney proximal tubules.

> Gene Ontology
 
Biological Process GO:0001951 intestinal D-glucose absorption
GO:0006814 sodium ion transport
GO:0007586 digestion
GO:0008643 carbohydrate transport
GO:0008645 hexose transport
GO:0015672 monovalent inorganic cation transport
GO:0015749 monosaccharide transport
GO:0015758 glucose transport
GO:0022600 digestive system process
GO:0034219 carbohydrate transmembrane transport
GO:0035428 hexose transmembrane transport
GO:0050892 intestinal absorption
GO:1904659 glucose transmembrane transport
Molecular Function GO:0005355 glucose transmembrane transporter activity
GO:0005412 glucose:sodium symporter activity
GO:0015077 monovalent inorganic cation transmembrane transporter activity
GO:0015081 sodium ion transmembrane transporter activity
GO:0015144 carbohydrate transmembrane transporter activity
GO:0015145 monosaccharide transmembrane transporter activity
GO:0015149 hexose transmembrane transporter activity
GO:0015291 secondary active transmembrane transporter activity
GO:0015293 symporter activity
GO:0015294 solute:cation symporter activity
GO:0015370 solute:sodium symporter activity
GO:0022804 active transmembrane transporter activity
GO:0046873 metal ion transmembrane transporter activity
GO:0051119 sugar transmembrane transporter activity
GO:1901476 carbohydrate transporter activity
Cellular Component GO:0005903 brush border
GO:0016324 apical plasma membrane
GO:0031253 cell projection membrane
GO:0031526 brush border membrane
GO:0045177 apical part of cell
GO:0098862 cluster of actin-based cell projections
> KEGG and Reactome Pathway
 
KEGG hsa04973 Carbohydrate digestion and absorption
hsa04976 Bile secretion
hsa04978 Mineral absorption
Reactome R-HSA-189200: Hexose transport
R-HSA-429593: Inositol transporters
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
R-HSA-428808: Na+-dependent glucose transporters
R-HSA-425407: SLC-mediated transmembrane transport
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-425366: Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
Summary
SymbolSLC5A1
Namesolute carrier family 5 (sodium/glucose cotransporter), member 1
Aliases D22S675; NAGT; sodium/glucose cotransporter 1; SGLT1; Na+/glucose cotransporter 1; high affinity sodium-gluc ......
Chromosomal Location22q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SLC5A1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSLC5A1
Namesolute carrier family 5 (sodium/glucose cotransporter), member 1
Aliases D22S675; NAGT; sodium/glucose cotransporter 1; SGLT1; Na+/glucose cotransporter 1; high affinity sodium-gluc ......
Chromosomal Location22q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SLC5A1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSLC5A1
Namesolute carrier family 5 (sodium/glucose cotransporter), member 1
Aliases D22S675; NAGT; sodium/glucose cotransporter 1; SGLT1; Na+/glucose cotransporter 1; high affinity sodium-gluc ......
Chromosomal Location22q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SLC5A1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4250.381
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0060.994
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.7440.309
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.0230.134
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.2840.271
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6960.603
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.8960.292
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-1.1080.452
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.7580.619
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.6430.666
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.2520.896
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.8490.0494
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SLC5A1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.11.49.70.0589
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.11.79.40.0895
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.811.8-70.577
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)1311018.2-18.20.199
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.67.4-4.80.565
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.515.4-10.90.541
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSLC5A1
Namesolute carrier family 5 (sodium/glucose cotransporter), member 1
Aliases D22S675; NAGT; sodium/glucose cotransporter 1; SGLT1; Na+/glucose cotransporter 1; high affinity sodium-gluc ......
Chromosomal Location22q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC5A1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSLC5A1
Namesolute carrier family 5 (sodium/glucose cotransporter), member 1
Aliases D22S675; NAGT; sodium/glucose cotransporter 1; SGLT1; Na+/glucose cotransporter 1; high affinity sodium-gluc ......
Chromosomal Location22q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC5A1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC5A1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSLC5A1
Namesolute carrier family 5 (sodium/glucose cotransporter), member 1
Aliases D22S675; NAGT; sodium/glucose cotransporter 1; SGLT1; Na+/glucose cotransporter 1; high affinity sodium-gluc ......
Chromosomal Location22q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC5A1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSLC5A1
Namesolute carrier family 5 (sodium/glucose cotransporter), member 1
Aliases D22S675; NAGT; sodium/glucose cotransporter 1; SGLT1; Na+/glucose cotransporter 1; high affinity sodium-gluc ......
Chromosomal Location22q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SLC5A1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSLC5A1
Namesolute carrier family 5 (sodium/glucose cotransporter), member 1
Aliases D22S675; NAGT; sodium/glucose cotransporter 1; SGLT1; Na+/glucose cotransporter 1; high affinity sodium-gluc ......
Chromosomal Location22q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SLC5A1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSLC5A1
Namesolute carrier family 5 (sodium/glucose cotransporter), member 1
Aliases D22S675; NAGT; sodium/glucose cotransporter 1; SGLT1; Na+/glucose cotransporter 1; high affinity sodium-gluc ......
Chromosomal Location22q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SLC5A1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting SLC5A1.
ID Name Drug Type Targets #Targets
DB08907CanagliflozinSmall MoleculeSLC5A1, SLC5A22